ReviewThe Lancet regional health. Europe2026
Artificial intelligence in the EU Safe Hearts Plan: prediction alone is not enough.
Review in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The European Commission's Safe Hearts Plan positions AI as a key tool for enhancing the prevention, diagnosis, and care of cardiovascular disease. Although AI presents significant opportunities, the Safe Hearts Plan may be overstating its impact by prioritising technological capacity over implementation readiness. This Viewpoint examines the role assigned to AI within the Safe Hearts Plan through a policy and legal analysis, drawing on EU policy documents, WHO/Europe reports, and literature on AI governance and cardiovascular care. It argues that a persistent "benefits gap" exists between AI's technical performance and its real-world clinical impact, reflecting institutional, operational, and legal barriers to implementation. The Viewpoint further analyses how legal uncertainty surrounding regulation, liability, and patients' rights may hinder the responsible integration of AI into cardiovascular care. It concludes that AI should be embedded within robust legal, institutional, and operational frameworks to improve cardiovascular outcomes rather than simply generate more accurate predictions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.